Subject: MEDICAL INDUSTRY INTERACTION

Originator: Mark T. Steele, M.D., Chief Medical Officer

Approval Date: April 13, 2011

Approved By: Catherine Disch, EVP/Chief Operating Officer

Mark T. Steele, M.D., Chief Medical Officer

Policy:
Interactions between employees and other persons connected with Truman Medical Centers (TMC), University of Missouri-Kansas City School of Medicine (UMKC) and University Physician Associates (UPA) (collectively, “the Institutions”) and representatives of the pharmaceutical and other medical industries shall be conducted so as to avoid or minimize conflicts of interest and to support the Institutions’ missions and values.

Purpose:
The primary objective of professional interactions between the Institutions and Industry shall be the advancement of the health of the population rather than the private good of either the Institutions or Industry. The Institutions intend by this Policy to promote the health of their patients, to protect the confidentiality of their patients, to ensure the integrity of their research activities, to slow the rising cost of healthcare, and to avoid perception of inappropriate financial gain by faculty, students, residents, and employees. The Policy, more specifically, should prevent any real or perceived undue influence by Industry Representatives and to establish guidelines for appropriate interactions with Industry Representatives.

Scope:
Except as otherwise specified in this Policy, Covered Persons are subject to this Policy only when present at property or facilities owned, leased or operated by the Institutions or at activities primarily sponsored by one or more of the Institutions. This Policy applies to the following interactions with Industry:
2. Access by Industry sales and marketing representatives.
3. Support for medical educational and professional activities.
Definitions:

Conflict of Interest – a situation in which someone or some entity has professional, financial, or personal interest(s) that compete significantly with the interests of the Institutions or their patients. Such competing interests can make it difficult to fulfill a Covered Person’s duties impartially. Even if there is no evidence of improper actions, a Conflict of Interest can create an appearance of impropriety that can undermine confidence in the ability of that Covered Person to act properly.

Covered Persons – all employees, volunteers, board members, members of medical staff, faculty, students, residents and fellows of the Institutions, and other individuals and entities working at property and facilities owned, leased or operated by the Institutions. Covered Persons include all Institutional entities and units consisting of one or more individual who is a Covered Person.

Family – spouse, partner, parent or dependent child.

Formulary – the current active medication or drug list maintained by the TMC Pharmacy and Therapeutics Committee.

Industry – Organizations and individuals that manufacture or sell pharmaceuticals or equipment, devices, supplies or other products that have a direct impact on patient care.

Industry Representative – a sales or marketing representative of an Industry member.

Research – a systematic investigation designed to develop or contribute to generalizable knowledge.

Significant Financial Interest – receipt in the past year, or expectation of the receipt, of value, including salary or other payments for services (e.g., consulting fees, honoraria, payments for advisory roles); research funding; equity interests (e.g., stocks, stock options, dividends or other ownership interests), and intellectual property rights (e.g., patents, copyrights or royalties from such rights) for a Covered Person. This does not include:

(a) Salary, royalties, or other remuneration from a Covered Person’s employer;
(b) Income from seminars, lectures, or teaching engagements sponsored by public or nonprofit entities;
(c) Income from service on advisory committees or review panels for public or nonprofit entities;
(d) An equity interest that when aggregated for the Covered Person or Family is not more than a $10,000 ownership interest in any single entity; or
(e) Pooled resources directly held through funds such as mutual funds, pension funds, or other institutional investment funds in which the Covered Person or the Family does not control the selection of investments.
Procedure:
I. Gifts, compensation, and meals

A. Except as otherwise permitted by this Policy, Covered Persons shall not request or accept any gifts from Industry Representatives, including payments, travel, hospitality, meals, tickets, favors or other goods or services, extending even to "reminder" items like pens and notepads. This prohibition shall not apply to gifts to patients, except sample medications, as set forth in the following Subsection I.B.

B. At TMC HH, TMC LW and TMC Behavioral Health, sample medications may be accepted only by the TMC Pharmacy Department. If Industry Representatives request a physician signature for delivery of samples (which is not required by law), the physician may meet with them in non-clinical areas (see Sub-section II.B. below). Prescriptions for medication samples may be written by individual practitioners as long as the samples are maintained and dispensed by the TMC Pharmacy Department at TMC HH, TMC LW and TMC BH. Covered Persons shall not dispense sample medications directly to patients. See TMC Policy on the intranet – Drug Samples


C. In addition to the terms of this Policy, all TMC personnel are bound by the TMC Code of Conduct (see heading "Gifts and Gratuities, Bribery").

D. Covered Persons may refer to the interaction and gift policies of the American Medical Association; U.S. Department of Health and Human Services Office of Inspector General - Compliance Program Guidance for Pharmaceutical Manufacturers; Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support; and Association of American Medical Colleges (AAMC).

See: www.ama-assn.org/ama/pub/category/8484.html
www.ama-assn.org/ama/pub/category/4263.html
http://oig.hhs.gov/authorities/docs/03/050503FRCPGPPharmac.pdf
www.ACCME.org
www.AAMC.org

E. The prohibitions in this Part I do not apply to a charitable gift to the TMC Charitable Foundation or other fund raising organizations, so long as the gift is not channeled to individuals for direct promotion of Industry products.

II. Access by Industry sales and marketing representatives
A. Prior to interacting with any Covered Person or visiting any unit of the Institutions, pharmaceutical Industry Representatives shall register with the TMC Pharmacy Department and non-pharmaceutical Industry Representatives shall register with the TMC Purchasing Department. All Industry Representatives shall pay the required annual fee, if not already paid, and receive a name badge to wear for appropriate identification while present at the Institutions.

B. Industry Representatives shall not enter clinical areas of the Institutions for any purpose with one exception. In the sole case of non-pharmaceutical products, Industry Representatives may access clinical areas by appointment, with approval from the appropriate Department Chair or Program Director, in coordination with the TMC manager/director of the clinical area, if the purpose is either

1. To provide needed in-service training or assistance on Industry products already purchased, or
2. To assist Covered Persons to evaluate new Industry products before purchasing them.

C. Appointments by Industry Representatives to discuss pharmaceutical information about non-Formulary drugs shall be issued only for non-clinical areas and only by the TMC Pharmacy Department or the TMC Pharmacy and Therapeutics (P&T) Committee. This sub-section does not, however, limit meetings between Industry Representatives and faculty in faculty offices or other private, non-clinical locations.

D. Announcements to Covered Persons about off-site events sponsored or funded by Industry shall not be made using Institutional communication mechanisms such as email, regular mail, flyers, brochures, bulletin boards, and posters, unless an Institution is the sponsor and the Industry support is regulated under one of the aforementioned guidelines, e.g., ACCME.

E. Industry Representatives shall comply with all laws and policies concerning patient confidentiality and shall not interact with patients, review any part of the medical record, attend patient rounds, or attend surgery, without written patient authorization.

F. All Covered Persons shall report any violations of this Policy on the TMC Compliance Concern Line – (866) 494-3600 – or another designated Institutional channel.

G. Industry Representatives shall be informed about this Policy and shall comply with its provisions.
H. If any Industry Representative violates this Policy, the sanctions shall be a written notice for the first offence, a 6-month suspension from the Institutions for the second offence, and a permanent ban from the Institutions for the third offence.

III. Support for medical education and professional activities

A. Industry support is solicited and appreciated in Continuing Medical Education (CME) or other professional activities designed to enhance the quality of care provided to patients. Because of the potential for undue Industry influence or speaker bias, the ACCME has strict standards for commercial support and influence in CME. See [www.ACCME.org](http://www.ACCME.org)
See also TMC Policy on the intranet – CME Department Policy
[http://tmcpolicy/Corporate/default.aspx](http://tmcpolicy/Corporate/default.aspx)

B. All educational events at TMC shall comply with ACCME Standards for Commercial Support, whether or not CME credit is awarded.

C. Industry support for the education of Covered Persons shall be channeled through the Institutions' CME Offices, shall be free of any real or perceived Conflicts of Interest, shall be specifically for the purpose of education, and shall comply with all of the following:

1. The funds are provided only to the Institution, not directly to the Covered Person.
2. The Institution selects the recipient of the funds for the educational activity.
3. The Institution, department, or program has determined the funding is for a program that has educational merit.

D. Covered Persons shall not accept compensation for attending an event or other activity or conference if the Person is not presenting at the event, organizing the meeting or serving in the capacity as a research study investigator or study staff for a funded research project. Even where compensation is thus permitted, it shall be limited to reasonable payment or reimbursement of ordinary and necessary travel, meals, and conference expenses.

E. Covered Persons shall carefully evaluate their own participation in off-site meetings or conferences that are fully or partially sponsored or funded by Industry, because of the high potential for perceived or real Conflicts of Interest.

F. Research grants or contracts from Industry shall require deliverable results of comparable value.

IV. Disclosure of Significant Financial Interests with Industry

A. All Covered Persons that conduct or engage in research activities at Institutions shall, in accordance with Institutional policies, disclose any Significant Financial
Interest that the Person currently has, or has had within the past year, with the research study sponsor. See TMC Policy on the intranet – Research-Protection of Human Subjects and the Conduct of Research http://tmcpolicy/Corporate/Corporate%20Policies%20and%20Procedures/Research%20-%20Protection%20of%20Human%20Subjects.doc

B. At the time of appointment to the P&T Committee and annually thereafter, all Committee members shall disclose to the full Committee the nature of any current or recent (within the past year) Significant Financial Interest they have with any pharmaceutical manufacturer or seller. This information shall be reiterated to the Committee each time the Committee considers a request for Formulary addition by the manufacturer or seller of a drug in which a member has a Significant Financial Interest. Any member of the P&T Committee who has any Significant Financial Interest shall abstain from discussion and voting on all requests, whether or not a drug under consideration is recommended for addition to the Formulary.

C. Any Covered Person requesting a Formulary change or otherwise presenting to the P&T Committee shall similarly disclose any Significant Financial Interest and abstain from discussion on all Formulary requests.

D. Covered Persons are prohibited from publishing articles written or funded in whole or material part by Industry, unless the Industry participation is fully disclosed.

E. In scholarly publications, Covered Persons shall disclose any related Significant Financial Interest in accordance with the standards of the International Committee of Medical Journal Editors (ICMJE). See www.ICMJE.org

F. Covered Persons that have a direct role in making institutional purchasing recommendations on Industry products shall disclose to the purchasing unit, prior to making a suggestion, any Significant Financial Interest of them or their Family that might substantially benefit from the recommendations. Covered Persons shall also disclose any research or educational interest they or their department have that might substantially benefit from the recommendation. See TMC Policy on the intranet – Conflict of Interest Policy and Procedure for Executives. http://tmcpolicy/Corporate/Corporate%20Policies%20and%20Procedures/Conflict%20of%20Interest%20Policy%20and%20Procedure%20for%20Executives.doc

G. Planners of and presenters at lectures and presentations shall disclose to the audience whether or not they or their Family have any financial interest in the manufacturer or seller of any product or service to be discussed in the course of the presentation or in the commercial supporter of the program at which they are speaking. See TMC Policy on the intranet – CME Department Policy http://tmcpolicy/Corporate/default.aspx
H. Faculty with supervisory responsibility for employees, students, residents or fellows should ensure that any actual or potential Conflict of Interest does not affect or appear to affect the supervision.

V. Training concerning Conflicts of Interest and interactions with Industry

All Covered Persons shall receive training about potential Conflicts of Interest and interactions with Industry.

Original Approval Date: March 30, 2004
Revised Dates: Jun 12, 2006
Revised Dates: May 14, 2008
Revised Dates: April 13, 2011
Revised Dates: 

Reviewed Date: July 23, 2010 Initials: MS
Reviewed Date: ______________ Initials: ______
Reviewed Date: ______________ Initials: ______
Reviewed Date: ______________ Initials: ______